FOLFOX Chemotherapy
Treatment for Stomach Cancer
Typical Dosage: Standard BSA-based regimen (Oxaliplatin 85mg/m2, Leucovorin 400mg/m2, 5-FU 400mg/m2 bolus + 2400mg/m2 infusion over 46h, bi-weekly)
Effectiveness
75%
Safety Score
25%
Clinical Trials
65
Participants
25K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Standard BSA-based regimen (Oxaliplatin 85mg/m2, Leucovorin 400mg/m2, 5-FU 400mg/m2 bolus + 2400mg/m2 infusion over 46h, bi-weekly)
Time to Effect
2-4 weeks
Treatment Duration
6 months (adjuvant) or until progression (palliative)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
3(Treat 3 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$20,000
Monitoring:$10,000
Side Effect Mgmt:$15,000
Total Annual:$45,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$110,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$112,500
Cost per Remission
$450,000
FOLFOX Chemotherapy Outcomes
for Stomach Cancer
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+40%
Remission Rate
+10%
Common Side Effects
Nausea/Vomiting
+70%
Neutropenia
+60%
Peripheral neuropathy (Oxaliplatin)
+70%
Diarrhea
+50%
Fatigue
+80%
Mucositis
+40%
Sources:
Active Clinical Trials
5 active trials recruiting for FOLFOX Chemotherapy in Stomach Cancer
sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
NCT05332002RECRUITINGPHASE2
38 participants
INTERVENTIONAL
Hamilton, United States +5 more
Started: Jul 13, 2022
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
NCT07070466NOT YET RECRUITINGPHASE2
40 participants
INTERVENTIONAL
Boston, United States
Started: Dec 12, 2025
PIPAC in Multimodal Therapy for Patients with Oligometastatic Peritoneal Gastric Cancer
NCT05303714RECRUITINGPHASE3
98 participants
INTERVENTIONAL
Verona, Italy
Started: Mar 31, 2022
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
NCT04421820RECRUITINGPHASE1, PHASE2
220 participants
INTERVENTIONAL
Santa Monica, United States +13 more
Started: Aug 28, 2020
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
NCT06846346RECRUITINGPHASE2
88 participants
INTERVENTIONAL
Lyon, France +3 more
Started: Nov 20, 2025
Completed Clinical Trials
9 completed trials for FOLFOX Chemotherapy in Stomach Cancer
BReast CAncer Genes(BRCA) Expressions in Metastatic Gastric Cancer
NCT03838406COMPLETEDNA
30 participants
INTERVENTIONAL
Seoul, South Korea
Started: Aug 1, 2017
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
NCT03662659COMPLETEDPHASE2
274 participants
INTERVENTIONAL
Clovis, United States +78 more
Started: Oct 16, 2018
PIPAC and FOLFOX for Gastric Cancer Peritoneal Cancer
NCT05644249COMPLETEDNA
37 participants
INTERVENTIONAL
Vilnius, Lithuania +1 more
Started: Dec 1, 2022
FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
NCT00673673COMPLETEDPHASE2
39 participants
INTERVENTIONAL
Hamden, United States +1 more
Started: May 1, 2008
Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy
NCT04526886COMPLETEDNA
52 participants
INTERVENTIONAL
Lebanon, United States
Started: Oct 15, 2020
S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma
NCT01364376COMPLETEDNA
583 participants
INTERVENTIONAL
Jinan, China +7 more
Started: Jun 1, 2011
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
NCT00982592COMPLETEDPHASE2
124 participants
INTERVENTIONAL
Sacramento, United States +29 more
Started: Sep 1, 2009
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
NCT03597581COMPLETEDPHASE1
89 participants
INTERVENTIONAL
Prescott Valley, United States +16 more
Started: Jun 5, 2018
FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
NCT01913639COMPLETEDPHASE2
39 participants
INTERVENTIONAL
Basking Ridge, United States +4 more
Started: Jul 1, 2013
Showing 20 of 67 total trials